Search
Gamcemetinib
go.drugbank.com/drugs/DB21624InvestigationalGamcemetinib is under investigation in clinical trial NCT04947579 (A Study of CC-99677 in Participants With Active Ankylosing Spondylitis). … Gamcemetinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Gamcemetinib is a tyrosine kinase inhibitor.
Dazdotuftide
go.drugbank.com/drugs/DB21550InvestigationalDazdotuftide is under investigation in clinical trial NCT05042609 (A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma). … Dazdotuftide has a monoisotopic molecular weight of 1005.48 Da.
Muvalaplin
go.drugbank.com/drugs/DB21568InvestigationalMuvalaplin is under investigation in clinical trial NCT05563246 (A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events). … Muvalaplin has a monoisotopic molecular weight of 710.4 Da.
Pocenbrodib
go.drugbank.com/drugs/DB21616InvestigationalPocenbrodib has a monoisotopic molecular weight of 525.23 Da. … Pocenbrodib is a small molecule drug.
Upleganan
go.drugbank.com/drugs/DB21618InvestigationalUpleganan is a small molecule drug. Upleganan is under investigation in clinical trial NCT04865393 (Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function). … Upleganan has a monoisotopic molecular weight of 1143.6 Da.
Atigliflozin
go.drugbank.com/drugs/DB21394InvestigationalAtigliflozin is under investigation in clinical trial NCT00361738 (Dose-Ranging Study Evaluating AVE2268 in Patients With Type 2 Diabetes Not Adequately Controlled by a Metformin Treatment). … Atigliflozin has a monoisotopic molecular weight of 382.11 Da.
Altropane I-123
go.drugbank.com/drugs/DB15144InvestigationalAltropane I-123 is under investigation in clinical trial NCT01950468 (A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the
Vilamakitug
go.drugbank.com/drugs/DB18978InvestigationalVilamakitug is under investigation in clinical trial NCT05201352 (Evaluation of Efficacy of Trifluridine/tipiracil Plus an Anti-il-1α True Human Antibody Versus Trifluridine/tipiracil Plus Placebo in Metastatic
Tasquinimod
go.drugbank.com/drugs/DB05861InvestigationalThe quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts
ETC-1001
go.drugbank.com/drugs/DB05866ExperimentalETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.